Manufacturers Life Insurance Company, The Vbi Vaccines Inc Transaction History

Manufacturers Life Insurance Company, The

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.12 - $4.65 $4,237 - $164,214	-35,315 Closed	0 $0
Q3 2022 Aug 11, 2023	SELL	$0.73 - $23.4 $31,236 - $1 Million	-42,790 Reduced 54.79%	35,315 $25,000
Q3 2022 Nov 03, 2022	BUY	$0.73 - $23.4 $25,779 - $826,371	35,315 New	35,315 $25,000
Q2 2022 Aug 15, 2022	SELL	$0.66 - $1.81 $51,549 - $141,370	-78,105 Closed	0 $0
Q1 2022 Aug 11, 2023	BUY	$1.27 - $2.47 $54,343 - $105,691	42,790 Added 121.17%	78,105 $129,000
Q1 2022 May 20, 2022	SELL	$1.27 - $2.47 $27,734 - $53,939	-21,838 Reduced 21.85%	78,105 $130,000
Q4 2021 Feb 16, 2022	BUY	$2.21 - $3.22 $3,160 - $4,604	1,430 Added 1.45%	99,943 $234,000
Q3 2021 Nov 12, 2021	SELL	$2.8 - $3.72 $17,242 - $22,907	-6,158 Reduced 5.88%	98,513 $286,000
Q2 2021 Aug 12, 2021	BUY	$2.61 - $4.17 $11,700 - $18,694	4,483 Added 4.47%	104,671 $351,000
Q1 2021 May 03, 2021	SELL	$2.91 - $4.32 $17,378 - $25,799	-5,972 Reduced 5.63%	100,188 $312,000
Q4 2020 Feb 12, 2021	BUY	$2.15 - $3.5 $18,911 - $30,786	8,796 Added 9.03%	106,160 $292,000
Q3 2020 Nov 09, 2020	SELL	$2.77 - $6.17 $7,855 - $17,498	-2,836 Reduced 2.83%	97,364 $278,000
Q2 2020 Aug 10, 2020	BUY	$0.87 - $3.13 $799 - $2,876	919 Added 0.93%	100,200 $314,000
Q1 2020 May 15, 2020	BUY	$0.73 - $1.91 $72,475 - $189,626	99,281 New	99,281 $94,000
Q2 2018 Aug 14, 2018	SELL	$2.75 - $3.85 $52,467 - $73,454	-19,079 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$3.5 - $4.47 $36,505 - $46,622	-10,430 Reduced 35.35%	19,079 $66,000
Q4 2017 Feb 08, 2018	BUY	$3.29 - $5.03 $97,084 - $148,430	29,509	29,509 $126,000

688K

Ticker VBIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 258,256,992
Market Cap $5.17M
Description
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The...

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.